Exscientia IPO Attracts Tech Investor Bets to AI Drug Discovery
Exscientia’s lucrative entry onto the Nasdaq last week demonstrated investors are still excited by efforts…
07/10/2021 - 5 minutes
Mark Zipkin
Mark Zipkin is a freelance writer and consultant for the biotech and pharma industry, and a Central Operations Analyst for safety app Citizen. He was previously a staff writer at BioCentury, and has worked for SpringerNature journals including Nature Biotechnology and Nature Neuroscience. Mark lives in New Jersey with his wife and three children. Follow Mark on Twitter @MarkZipkin.
How to Choose the Right Headquarters for Your Biotech Startup
Choosing where to plant your biotech company’s roots is a fundamental question driven by access…
05/10/2021 - 6 minutes
How to Pitch Your Biotech Startup to a Life Sciences Investor
You’ve got the idea. You’ve got the science. You’ve got the team. Now all you…
18/08/2021 - 9 minutes
Sanofi’s Translate Bio Buyout Shows Growing Hunger for mRNA Technology
Sanofi’s acquisition of its partner Translate Bio is a clear sign that pharmaceutical companies are…
17/08/2021 - 5 minutes
Microbiome Medicines Could Power Up CAR-T Cell Therapies
The microbiome could pave new cancer immunotherapy inroads for European biotechs, bolstered by preclinical findings…
28/07/2021 - 5 minutes
How to Protect Your Intellectual Property as a Biotech Startup
Biotechs always start with great scientific ideas, but if you can’t protect them, you can’t…
19/07/2021 - 9 minutes
What Makes a Biotech Executive Stand Out?
Talented executives are always in demand in the biotech industry. Leaders who stand out in…
16/06/2021 - 6 minutes
Startup Creator Launched to Fill Europe’s Microbiome Translational Gap
With a €49M ($60M) Series A, the French firm eureKARE debuted this month with the…
28/05/2021 - 6 minutes
How to Spend Your Biotech Startup’s Money
Biotech investment rounds tend to draw big headlines, but experienced players know the real work…
17/05/2021 - 6 minutes
BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors
Bristol Myers Squibb’s recent phase III success provided the first late-stage confirmation for a novel…
29/04/2021 - 5 minutes
Achilles Therapeutics’ IPO Caps Investment Wave for Neoantigens
The close of the UK firm Achilles Therapeutics’ €146.9M ($175.5M) initial public offering last month…
15/04/2021 - 5 minutes
Have European Investors Missed the Exosome ‘Gold Rush’?
When Oxford-based Evox Therapeutics announced its €81.1M (£69.2M) Series C round in February, it signaled…
01/04/2021 - 5 minutes
